Related Experiment Videos
[Febrile toxiderma in children]
M Larrègue1, P Vabres, F Auriol
1Service de dermatologie Centre hospitalier universitaire, Poitiers.
Insights
Diagnosing febrile cutaneous drug reactions in children is challenging due to similar symptoms with infections and allergies. Clinical evaluation is key for identifying the causative drug and ensuring patient safety.
Area of Science:
- Pediatric Dermatology
- Clinical Pharmacology
- Drug Safety
Context:
- Febrile cutaneous drug reactions account for 6% of pediatric dermatologic hospitalizations.
- Distinguishing drug reactions from infections is challenging due to overlapping symptoms.
- Multiple drugs can cause similar eruptions, and a single child may have various causes for skin issues.
Purpose:
- To highlight the diagnostic challenges in febrile cutaneous drug reactions in children.
- To emphasize the importance of clinical evaluation and imputability in diagnosis.
- To discuss the limited role of paraclinical methods and the necessity of drug withdrawal.
Summary:
- Clinical diagnosis and clinical imputability are the primary methods for diagnosing drug-induced skin reactions in children.
- Paraclinical investigations offer limited diagnostic value.
- Immediate symptomatic treatment is initiated upon admission, followed by withholding the suspected drug.
Impact:
- Facilitates accurate diagnosis and management of drug-induced skin reactions in pediatric patients.
- Informs healthcare providers about the diagnostic approach and the importance of drug withdrawal.
- Contributes to post-marketing surveillance by reporting identified causative drugs.
Abstract:
Febrile cutaneous drug reactions in the child represent 6% of paediatric hospitalizations for dermatologic reasons. Diagnosis is difficult, for both infectious diseases and drug allergy can induce the same skin reaction. The same eruption can correspond to several drug-induced reactions. In a single child, there may be several causes of skin eruption and several drugs inducing similar cutaneous reactions. Clinical diagnosis and the method of clinical imputability lead to diagnosis. Paraclinical methods are of limited interest. Symptomatic treatment is begun on emergency admission. Upon identification, the responsible drug can be withheld and the authorities responsible for post-marketing surveillance can be notified.